271 related articles for article (PubMed ID: 21370258)
1. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease.
Stowe R; Ives N; Clarke CE; Handley K; Furmston A; Deane K; van Hilten JJ; Wheatley K; Gray R
Mov Disord; 2011 Mar; 26(4):587-98. PubMed ID: 21370258
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
[TBL] [Abstract][Full Text] [Related]
3. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
Deane KH; Spieker S; Clarke CE
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004553. PubMed ID: 15495118
[TBL] [Abstract][Full Text] [Related]
4. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE;
JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574
[TBL] [Abstract][Full Text] [Related]
5. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
Deane KH; Spieker S; Clarke CE
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004554. PubMed ID: 15495119
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T
Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702
[TBL] [Abstract][Full Text] [Related]
7. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
Najib J
Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
[TBL] [Abstract][Full Text] [Related]
8. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Jankovic J; Stacy M
CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
[TBL] [Abstract][Full Text] [Related]
9. Dopamine agonist therapy in early Parkinson's disease.
Stowe RL; Ives NJ; Clarke C; van Hilten J; Ferreira J; Hawker RJ; Shah L; Wheatley K; Gray R
Cochrane Database Syst Rev; 2008 Apr; (2):CD006564. PubMed ID: 18425954
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
Talati R; Reinhart K; Baker W; White CM; Coleman CI
Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of different catechol-o-methyl transferase inhibitors for patients with parkinson's disease: Systematic review and network meta-analysis.
Wu W; Lu X; Zhang L; Hong D
Clin Neurol Neurosurg; 2024 Apr; 239():108189. PubMed ID: 38437773
[TBL] [Abstract][Full Text] [Related]
12. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
Kulisevsky J; Pagonabarraga J
Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
Poewe WH; Deuschl G; Gordin A; Kultalahti ER; Leinonen M;
Acta Neurol Scand; 2002 Apr; 105(4):245-55. PubMed ID: 11939936
[TBL] [Abstract][Full Text] [Related]
14. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients.
Ives NJ; Stowe RL; Marro J; Counsell C; Macleod A; Clarke CE; Gray R; Wheatley K
BMJ; 2004 Sep; 329(7466):593. PubMed ID: 15310558
[TBL] [Abstract][Full Text] [Related]
15. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
[TBL] [Abstract][Full Text] [Related]
16. Uncertainties in the pharmacotherapy of Parkinson's disease and how to solve them.
Overstall PW; Clarke CE
Gerontology; 2002; 48(1):30-3. PubMed ID: 11844927
[TBL] [Abstract][Full Text] [Related]
17. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
; Gray R; Ives N; Rick C; Patel S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE
Lancet; 2014 Sep; 384(9949):1196-205. PubMed ID: 24928805
[TBL] [Abstract][Full Text] [Related]
18. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.
Binde CD; Tvete IF; Gåsemyr J; Natvig B; Klemp M
Br J Clin Pharmacol; 2018 Sep; 84(9):1917-1927. PubMed ID: 29847694
[TBL] [Abstract][Full Text] [Related]
19. Levodopa-related wearing-off in Parkinson's disease: identification and management.
Pahwa R; Lyons KE
Curr Med Res Opin; 2009 Apr; 25(4):841-9. PubMed ID: 19228103
[TBL] [Abstract][Full Text] [Related]
20. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
